Skip to main content
. 2015 Dec 17;7(1):100–104. doi: 10.1021/acsmedchemlett.5b00428

Figure 1.

Figure 1

(A) Crystal structure of the apo-TMLR double mutant (PDB 5EDP). The pocket surface is shown in gray. Compound 2 is overlaid. (B) X-ray structure of compound 2 with the TMLR double mutant. Hinge residues Met793 and Gln791 are shown. The pocket surface is shown in gray. (C) Overlay of compound 2 (cyan) with the erlotinib crystal structure with wtEGFR (orange) showing the pocket created by Thr790 (gray surface) (PDB 1M17). (D) Structure of erlotinib with biochemical potency in wtEGFR and TMLR.